文献速递甲状腺与浅表US

射频消融治疗≤2 cm Bethesda IV类甲状腺结节的体积缩小率

Volume reduction rate of radiofrequency ablation in ≤ 2 cm Bethesda IV thyroid nodules.
PubMed 文献 · Eur Radiol · 2023-09-04

这项前瞻性观察研究纳入62例≤2 cm、Bethesda IV类、C-TIRADS 4A类甲状腺结节,行超声引导下射频消融,评估体积缩小率与完全吸收情况,发现RFA有效,且3级血供与慢性甲状腺炎影响完全吸收。

要点

  • ≤2 cm Bethesda IV类甲状腺结节行RFA后1年超半数结节体积缩小率达90%以上。
  • 研究结束时88.7%的结节达到完全吸收,随访14至63个月。
  • 3级血供结节与合并慢性甲状腺炎者第12个月完全吸收延迟(p=0.036与0.003)。

核心结论

  • RFA是治疗≤2 cm、Bethesda IV类细胞学且C-TIRADS 4A类甲状腺结节的有效技术,3级血供与慢性甲状腺炎影响消融后完全吸收。

研究设计与样本

  • 前瞻性观察研究,共62例62个结节接受超声引导下RFA,随访评估体积缩小率与完全/不完全吸收。

关键影像表现/征象

  • 第1、3、6、12个月及末次随访的平均体积缩小率分别为-88.6%、16.0%、59.7%、82.0%和98.2%。
  • RFA后1年超过半数结节体积缩小率达90%。
  • 研究结束时88.7%的结节达到完全吸收(随访14至63个月)。
  • 第12个月随访时,3级血供结节与合并慢性甲状腺炎者完全吸收延迟(p=0.036和0.003)。

临床应用与阅片要点

  • 评估≤2 cm Bethesda IV类、C-TIRADS 4A类甲状腺结节RFA疗效时可参考体积缩小率与完全吸收情况。
  • 阅片报告时注意结节血供分级(3级)及是否合并慢性甲状腺炎,二者与完全吸收延迟相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This prospective observational study aimed to evaluate the efficacy of radiofrequency ablation (RFA) in treating ≤ 2 cm thyroid nodules with Bethesda IV cytology and C-TIRADS 4A categorization. Additionally, the factors influencing the completed absorption of ablation (CAA) were examined.

METHODS: A total of 62 cases with 62 nodules underwent ultrasound-guided RFA and were included in the study. The volume reduction rate (VRR), CAA, and incomplete absorption of ablation (IAA) were assessed at the 1st, 3rd, 6th, and subsequent 6-month follow-ups. Clinical and ultrasound features were compared between the CAA and IAA groups at the 12th month follow-up.

RESULTS: The average VRR at the 1st, 3rd, 6th, 12th month, and last follow-up were -88.6%, 16.0%, 59.7%, 82.0%, and 98.2%, respectively. More than half of the nodules achieved a 90% VRR after 1 year of RFA, with 88.7% demonstrating CAA at the end of the study (follow-up duration of 14 to 63 months). Nodules with grade 3 vascularity and those associated with chronic thyroiditis showed delayed CAA at the 12th month follow-up (p = 0.036 and 0.003, respectively).

CONCLUSION: RFA is an effective technique for treating ≤ 2 cm thyroid nodules with Bethesda IV cytology and C-TIRADS 4A categorization. Nodules with grade 3 blood supply and patients with chronic thyroiditis exhibited an impact on the completed absorption following RFA.

CLINICAL RELEVANCE STATEMENT: Our study has shown that radiofrequency ablation is an effective treatment for ≤ 2 cm thyroid nodules classified as Bethesda IV cytology. However, we identified that high vascularity of the nodule and chronic thyroiditis are adverse factors affecting the completed absorption of the ablation.

KEY POINTS: •Radiofrequency ablation (RFA) is an effective technique for treatment of ≤ 2 cm Bethesda IV category thyroid nodules. •Higher blood supply and chronic thyroiditis influence the completed absorption after RFA.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Dong Y, Zhan W, Zhou J, et al. Volume reduction rate of radiofrequency ablation in ≤ 2 cm Bethesda IV thyroid nodules. Eur Radiol. 2023. PMID: 37665388. doi:10.1007/s00330-023-10185-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。